Company: AEMD
Filing Date: 2025-09-09
Form Type: 8-K
Source: 0001683168-25-006788
Chunk: 1

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-09
Form: 8-K
Item: Item 1.01
Chunk 1
---
% of the aggregate gross proceeds of the Offering (amounting to $281,250) at closing, as well as $100,000
for the reimbursement of certain of the Placement Agent’s expenses. Additionally, the Company issued to the Placement Agent, as
part of the Placement Agent’s compensation, 200,000 warrants to purchase up to an aggregate of 200,000 shares of Common Stock, equal
to 4.0% of the aggregate number of Shares placed in the Offering. The Placement Agent Warrants have a term of five (5) years from the
commencement of sales under the Offering, are exercisable commencing six (6) months from the closing date, and have an exercise price
of $0.90 per share of Common Stock (equal to 100% of the combined public offering price per Common Unit).

The Company received
gross proceeds from the Offering of $4.5 million, before deducting Placement Agent fees and other offering expenses payable by the Company.
The net proceeds to the Company from the Offering, after deducting the Placement Agent’s fees and expenses and estimated offering
expenses (excluding proceeds to the Company, if any, from the future exercise of the Common Warrants and Placement Agent Warrants), were
approximately $3.9 million. The Company intends to use the net proceeds from the Offering as working capital for general corporate purposes.

In conjunction with the
closing of the Offering, the Company entered into a Warrant Agency Agreement with Computershare Inc. (“ Computershare Inc.”)
and its affiliate, Computershare Trust Company, N. A. (“ Computershare Trust”) (collectively Computershare, Inc. and Computershare
Trust, “ Computershare”) pursuant to which Computershare agreed to act as warrant agent with respect to the Warrants issued
by the Company in the Offering.

In addition, the Company
(i) has agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of the Company’s
(or its subsidiary’s) securities for a period of ninety (90) days from the closing of the Offering, subject to certain exceptions
and (ii) shall not effect or enter into an agreement to effect, any issuance by the Company or any of its subsidiaries of common stock
or common stock equivalents (or a combination of units thereof) involving a variable rate transaction for a period of one (1) year from
the closing of the Offering. Additionally, in connection